Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
This change lagged the S&P 500's daily loss of 0.13%. On the other hand, the Dow registered a gain of 0.11%, and the technology-centric Nasdaq decreased by 0.72%. The stock of biotechnology company has risen by 9.29% in the past month, leading the Medical sector's loss of 2.41% and the S&P 500's gain of 0.78%. Investors will be eagerly watching for the performance of Recursion Pharmaceuticals in its upcoming earnings disclosure. The company is expected to report EPS of -$0.28, up 47.17% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $25.5 million, up 460.44% from the year-ago period. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$1.59 per share and revenue of $64.62 million. These totals would mark changes of +5.92% and 0%, respectively, from last year. Investors should also pay attention to any latest changes in analyst estimates for Recursion Pharmaceuticals. Th
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural ShiftPR Newswire
- Is Recursion Pharmaceuticals Inc. (RXRX) The Best Overlooked Penny Stock to Invest In? [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 11/5/25 - Beat
RXRX
Sec Filings
- 1/22/26 - Form 4
- 1/20/26 - Form 144
- 1/12/26 - Form 8-K
- RXRX's page on the SEC website